Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on LinkedIn:
“New Molecules to Look Forward to in GI Cancers – ESMO 2025
The GI oncology pipeline is evolving rapidly, and this year’s ESMO25 will showcase several exciting first-in-class and practice-shaping molecules. These agents target some of the toughest resistance mechanisms and tumor subsets in GI cancers.
Here are the key new molecules to watch:
- KRAS G12D inhibitors – GFH375, HRS-4642, INCB161734 – early clinical activity in pancreatic cancer and across GI cohorts.
- Zanzalintinib + Atezolizumab – VEGFR/MET/AXL TKI + IO (STELLAR-303, mCRC).
- Sirexatamab (DKN-01) – novel anti-DKK1 antibody combined with bevacizumab + chemo in MSS mCRC (LBA34).
- RC118 – CLDN18.2-directed ADC in gastric/GEJ cancers (LBA83).
- Telisotuzumab Adizutecan (ABBV-400) – c-MET–directed ADC with emerging signals in PDAC and CRC.
- Nofazinlimab + Lenvatinib – PD-1 + TKI in HCC (LBA52).
- Tiragolumab + Atezolizumab + Bevacizumab – Anti-TIGIT triplet in HCC (LBA50).
- Bemarituzumab + Chemo – FGFR2b-targeted, gastric/GEJ (Presidential LBA10).
These studies highlight the next wave of targeted therapies, ADCs, and novel immunotherapy combinations that could redefine treatment paradigms in GI cancers.
Looking forward to detailed data readouts at ESMO25 and how these molecules may impact real-world practice in LMICs as well as globally.”
More posts featuring Amol Akhade.